RSV MUCOSAL VACCINE
|Posted date||Mar 22, 2013|
|International application number||2012JP071831|
|International publication number||WO 2013031827|
|Date of international filing||Aug 29, 2012|
|Date of international publication||Mar 7, 2013|
|Title||RSV MUCOSAL VACCINE|
|Abstract||Provided is a composition comprising: an AD vehicle comprising a synthetic peptide and a lipid, wherein the synthetic peptide comprises an amino acid sequence represented by the formula KnLm (wherein n represents a number of 4 to 8 and m represents a number of 11 to 20); a carboxyvinyl polymer; and an RSV antigen. When the composition is used as a mucosal vaccine, the composition exhibits a higher antibody-producing ability than those of conventional mucosal vaccines. Consequently, the composition can exhibit an excellent effect of inducing an anti-viral antigen-specific IgA antibody and an anti-viral antigen-specific IgG antibody in a nasal lavage fluid and a serum, respectively, even when the RSV antigen is contained in the composition in an extremely small amount.|
|Outline of related art and contending technology||
Patent Document 1 and 2 is, like the conventional inactivated vaccines or the disadvantages of the toxoid, such as immune adjuvants and mucosal vaccine development of current has been described in detail.
These Patent Documents 1, as described in 2, such as conventional intramuscular subcutaneously inoculated into from a vaccine, is the root of a natural infection of the virus to induce the production of the antibody IgA mucosa of switching to the mucosal vaccine need, wider and deeper recognized. In particular, as the next generation vaccine 21 st century, the production of antibodies IgA, inducing an immune response or mucosal local immune, so-called mucosal vaccine development and practical use is possible for the deficiencies of all over the world, not yet been achieved.
The present inventors to solve this problem, (1) lung surfactant or lung surfactant B and C and the lipid/antigen complex (AD) drug vehicle, and the vehicle as (2) well as AD from mucosal vaccine antigen, and filed a patent application (Patent Document 1) are. Further the present inventors have found, and the amount of the antigen (V) vehicle AD (A) the amount of the weight ratio of V/A by adjusting the size, and the specific production and selection of antibodies IgA IgG IgA both antibody production and can be converted to found, this mechanism of action and a mucosal vaccine (Patent Document 2) are filed a patent application. These patents Document 1, is 2, a fragment of a lung surfactant C B and the validity of the (peptide) is disclosed.
Further the present inventors have, for various variants of pulmonary surfactant fragment antibody production enhancing effect as a result of studies, Patent Document 1, a partial peptide disclosed in 2 smaller in size than that in spite of the peptide, or a strong induction of antibody production enhancing effect, in particular, production of secretory IgA antibodies alone, the, both IgG and secretory IgA antibody production in the blood that has superior effective guidance has the effect of synthetic peptide KnLm (however n is 4-8, m is 11-20) and the lipids AD vehicle component (hereinafter, 'AD vehicle (a) ' abbreviated) and, from this AD vehicle (a) mucosal vaccine antigen, and filed a patent application (Patent Document 3) are. The invention described in the above-mentioned patent document 1-3, having a general-purpose properties are related to the mucosal vaccine, as described in the Examples was verified using the influenza virus is identified.
On the other hand, mucosal vaccine is an influenza virus other than respiratory disease causing virus has been studied. Among these RSV is a major cause of the cold syndrome and one of the virus, infection of life many times difficult from one virus immune acquisition 1. RSV infection the baby, the elderly, immunodeficiency patient bronchiolitis, cause pneumonia, particularly in the lower respiratory tract of the baby flame to about 30%. Of which need hospitalization and severe 1-3% vaccine appear can be been desired earnestly. Belonging to the Paramyxoviridae family virus is RSV RNA, and subtype B A large divided into subtypes. Fusion with the host cell is on the viral surface protein important F (non-patent document 1), g protein involved in adhesion to host cells (non-patent document 1), the presence of the protein SH is known. Therefore, these proteins all particles of the virus and many of the antigen has been studied RSV vaccine.
Usually, virus vaccine in the first attempt of formalin inactivated vaccine. Sufficient in this method in influenza virus vaccine efficacy to be obtained, formalin inactivated vaccines are long have been used. 1960 In formalin inactivated RSV vaccine era is attempted, unlike the case of the influenza virus, in RSV vaccine effect is not obtained, caused severe side effects in a reverse of the baby. (Non-patent document 2) thereafter, part of the constituting components RSV virus in a vaccine and an adjuvant mixed-to-split vaccines has been studied (patent document 4, patent document 5). RSV vaccine development attempts to date, the specific antigen which is capable of protection against infection as an attempt to, the development of effective adjuvant for, vaccination strategies has been the development is performed. So far, antibody-induced protection against infection by the new inactivation method (non-patent document 3) reports, membrane fusion RSV F proteins useful as antigens (non-patent document 4) reports that, g of RSV proteins useful as antigens (non-patent document 5) reports that and, depending on a manner of antigen administered as a vaccine, an antigen and an adjuvant added by the difference in the combination of, are in a variety of results of the current. But still vaccine effect is insufficient, or side effects has been sold to date by the approval and there is no RSV vaccine.
|Scope of claims||
(In Japanese)請求の範囲 [請求項1]
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
※ Please contact us by E-mail or facsimile if you have any interests on this patent.
Contact Information for " RSV MUCOSAL VACCINE "
- The University of Tokushima Department of Industry-Academia Collaboration Research Planning, Intellectual Property Office
- URL: https://www.tokushima-u.ac.jp/ccr/
- Address: 2-1, Minamijosanjima-cho, Tokushima-city, Tokushima , 770-8506
- Phone: 81-88-656-7592
- Fax: 81-88-656-7593